Skip to content
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
  • Home
  • News
  • Videos
  • Conference Coverage
  • Podcasts
  • Resource Centers
    • Acne
    • Skin Cancer
    • Alopecia
    • Atopic Dermatitis
    • Cosmetics
    • Hidradenitis Suppurativa (HS)
    • Pediatrics
    • Pigment Disorders
    • Practice Management
    • Psoriasis
    • Rare Diseases
    • Rosacea
    • Vitiligo
Subscribe

US FDA Accepts NDA for Bezuclastinib in Advanced Systemic Mastocytosis

The US Food and Drug Administration (FDA) has accepted Cogent Biosciences, Inc.’s New Drug Application (NDA) for bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027.

The Dermatology Digest is an independent, multi-channel resource for practicing dermatologists and dermatological practitioners.

Quick Links
  • Advertise with Us
  • About Us
  • Advertise with Us
  • About Us
Follow us
Linkedin Facebook-f X-twitter Youtube

© 2026 All Rights Reserved.